BPC-157 vs CJC-1295: Research Literature Comparison
BPC-157 and CJC-1295 appear together in search far more often than they appear together in published methodology. That gap is the useful part.
Side-by-side research profile
| Parameter | BPC-157 | CJC-1295 |
|---|---|---|
| PubMed indexed records | 228 | 33 |
| Registered studies (ClinicalTrials.gov) | 4 | 1 |
| Literature depth | Moderate | Emerging |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Compound profiles
BPC-157 in the indexed record
BPC-157 returns 228 indexed records on PubMed, a moderate record, alongside 4 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Altern Ther Health Med, Cell Tissue Res, Curr Rev Musculoskelet Med, spanning 2019–2025.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain — Altern Ther Health Med, 2021. PMID: 34324435
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — HSS J, 2025. PMID: 40756949
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Cell Tissue Res, 2019. PMID: 30915550
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review — Pharmaceuticals (Basel), 2025. PMID: 40005999
CJC-1295 in the indexed record
Indexed output for CJC-1295 stands at 33 records, a limited literature, alongside 1 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Am J Sports Med, Growth Horm IGF Res, J Am Acad Orthop Surg Glob Res Rev, spanning 2006–2026.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — J Clin Endocrinol Metab, 2006. PMID: 16352683
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026. PMID: 41476424
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions — Subst Use Misuse, 2016. PMID: 26771670
How the literature differs
The indexed record is not symmetrical between these two compounds. BPC-157 carries 195 more indexed records than CJC-1295, which means published methodology, characterisation data and replication attempts are more readily located for BPC-157. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (4 vs 1) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Classification and why it matters
BPC-157 and CJC-1295 sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for BPC-157 describes conditions validated for BPC-157: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to CJC-1295 without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
What the paperwork has to show
A certificate of analysis is only meaningful when it names the lot printed on the vial. Purity by HPLC and identity by mass spectrometry answer two different questions, and a document reporting one is not evidence of the other.
Selecting between them for a study design
BPC-157 and CJC-1295 are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (BPC-157) generally offers more methodological precedent.
Frequently asked questions
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Are BPC-157 and CJC-1295 the same compound?
No. They are structurally distinct research compounds with separate literature records — 228 indexed records for BPC-157 and 33 for CJC-1295.
Which of BPC-157 or CJC-1295 has more published research?
BPC-157, with 228 indexed PubMed records against 33.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Related references
- BPC-157 — product and lot documentation
- CJC-1295 — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.